{"id":"NCT03180840","sponsor":"Protalix","briefTitle":"Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks","officialTitle":"Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-10","primaryCompletion":"2020-08-01","completion":"2020-08-01","firstPosted":"2017-06-08","resultsPosted":"2023-01-05","lastUpdate":"2023-09-13"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fabry Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Pegunigalsidase alfa","otherNames":["PRX-102","Recombinant human alpha galactosidase-A"]}],"arms":[{"label":"Pegunigalsidase alfa","type":"EXPERIMENTAL"}],"summary":"This open-label switchover study will assess the safety, efficacy, and pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg administered every 4 weeks for 52 weeks in Fabry patients previously treated with ERT: agalsidase alfa or agalsidase beta for at least 3 years. Safety and efficacy exploratory endpoints will be evaluated throughout the study period and pharmacokinetics will be obtained on Day 1 and Week 52.","primaryOutcome":{"measure":"Number of Participants With Treatment-related Adverse Events (TEAE) as Assessed by CTCAE v4.03","timeFrame":"Month 12","effectByArm":[{"arm":"PRX-102","deltaMin":27,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States","Belgium","Czechia","Denmark","Italy","Norway","United Kingdom"]},"refs":{"pmids":["39847314"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":30},"commonTop":["Nasopharyngitis","Infusion related reaction","Fatigue","Cough","Nausea"]}}